# TNBC molecular subtyping

Source: https://onco.cc/terms/tnbc-molecular-subtyping/  
OnCo record `tnbc-molecular-subtyping` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TNBC RNA subtyping compares gene-expression patterns under a named research classifier. Tissue mixture, method and version matter, and the result is separate from receptor tests or a treatment choice.

## Summary

Lehmann's original TNBCtype system described six expression groups: BL1, BL2, IM, M, MSL and LAR. The 2016 TNBCtype-4 refinement retained BL1, BL2, M and LAR as tumour-focused profiles after evaluating immune and stromal contributions to the IM and MSL signals. Removed-profile samples were reassigned to their second-highest correlated tumour-profile centroid, not automatically to M.

BL1 is associated with cell-cycle/DNA-damage-response programmes; BL2 with growth-factor and myoepithelial-associated expression; M with motility and differentiation; and LAR with luminal and androgen-related transcription. These are classifier associations, not proof of one cause, functional repair deficiency or dependence on an inhibitor.

## Fields

- Kind: Term
- Last checked: 2026-11-09
- Also known as: TNBCtype; TNBCtype-4; Lehmann subtypes; TNBC expression subtypes
- Tags: education-audit; classification

## Notes

- Record tissue identity, timing relative to treatment, tumour content, RNA qualification, platform, gene coverage, preprocessing, normalisation, reference data, classifier/version and competing correlations. A reported correlation or permutation p-value is not automatically a probability. No universal RNA-quality cutoff qualifies every platform.
- A mixed-tissue IM signal and a BL1 call from an enriched preparation can coexist without proving tumour evolution. Compare preparation, method and scores. Tumour-focused labels do not make every bulk input free of immune or stromal RNA.
- PAM50 basal-like, AR protein positivity, an RNA LAR label, histology and receptor-defined TNBC are separate measurements. A lineage-associated programme does not establish an exact cell of origin.
- The defining cell-model and retrospective chemotherapy studies generated treatment hypotheses. Prospective strategy research also exists: FUTURE-SUPER used a distinct Fudan classifier plus genomic biomarkers and compared matched regimens with nab-paclitaxel alone. Its pooled phase 2 result does not validate every same-named profile or isolate the value of a classifier from its treatment bundle.

## Sources

- Lehmann 2011: original expression profiles and cell-model experiments: https://pubmed.ncbi.nlm.nih.gov/21633166/
- Lehmann 2016: tissue attribution and TNBCtype-4 refinement: https://pubmed.ncbi.nlm.nih.gov/27310713/
- Chen 2012: TNBCtype input and reported correlation/permutation statistics: https://pubmed.ncbi.nlm.nih.gov/22872785/
- Zhao 2020: specified Fudan research IHC classifier: https://pubmed.ncbi.nlm.nih.gov/32406563/
- FUTURE-SUPER primary randomised phase 2 report: https://pubmed.ncbi.nlm.nih.gov/38211606/

## Connected records

- terms: [Basal-like breast cancer](https://onco.cc/terms/basal-like/), [Luminal androgen receptor (LAR) subtype](https://onco.cc/terms/luminal-androgen-receptor/), [PAM50 / intrinsic subtypes](https://onco.cc/terms/pam50/)
- trials: [FUTURE-SUPER](https://onco.cc/trials/future-super/)
- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- key papers: [FUTURE-SUPER: first-line subtyping-based treatment in advanced TNBC](https://onco.cc/key-papers/paper-future-super-lancet-oncology-2024/), [Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies](https://onco.cc/key-papers/paper-lehmann-tnbc-subtypes-jci-2011/), [Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection](https://onco.cc/key-papers/paper-lehmann-tnbctype-4-refinement-plos-one-2016/)

---
JSON: https://onco.cc/api/v1/entities/tnbc-molecular-subtyping.json